| Literature DB >> 27153073 |
Yang-Mei Zhang1, Hong-Yu Li2, Chen Hu3, Hui-Fan Sheng4, Ying Zhang5, Bi-Run Lin6, Guang-Xiong Zhou7.
Abstract
An actinomycete strain, H41-59, isolated from sea sediment in a mangrove district, was identified as Streptomyces anandii on the basis of 16S rDNA gene sequence analysis as well as the investigation of its morphological, physiological and biochemical characteristics. Three new ergosterols, ananstreps A-C (1-3), along with ten known ones (4-13), were isolated from the culture broth of this strain. The gross structures of these new compounds were elucidated on the basis of extensive analysis of spectroscopic data, including HR-ESI-MS, and NMR. The cytotoxicities of these isolates against human breast adenocarcinoma cell line MCF-7, human glioblastoma cell line SF-268, and human lung cancer cell line NCI-H460 and their antibacterial activities in inhibiting the growth of Candida albicans and some other pathogenic microorganisms were tested. Compounds 3-8, 10 and 11 displayed cytotoxicity with IC50 values in a range from 13.0 to 27.8 μg/mL. However, all the tested compounds showed no activity on C. albicans and other bacteria at the test concentration of 1 mg/mL with the paper disc diffusion method.Entities:
Keywords: Streptomyces anandii; ananstreps A–C; cytotoxicity; ergosterols; strain identification
Mesh:
Substances:
Year: 2016 PMID: 27153073 PMCID: PMC4882558 DOI: 10.3390/md14050084
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Structures of compounds 1–13.
Figure 2The key HMBC, H1-H1 COSY (left) and NOESY (right) correlations of 1.
Figure 3The key HMBC, H1–H1 COSY (left) and NOESY (right) correlations of 2.
Figure 4The key HMBC, H1-H1 COSY (left) and NOESY (right) correlations of 3.
1H NMR spectral data of new compounds 1–3 (300 MHz for 1H, J in Hz).
| No. | 1a | 2a | 3a | 3b |
|---|---|---|---|---|
| 1 | 1.30, m | 1.15, m | 1.61, m | 1.74, m |
| 1.47, m | 2.05, m | |||
| 2 | 1.24, m | 1.31, m | 1.45, m | 1.62, m |
| 1.60, m | 1.67, m | 1.75, m | 1.95, m | |
| 3 | 3.76, m | 3.76, m | 3.53, m | 3.91, m |
| 4 | 1.49, m | 1.47, m | 1.20, m | 1.45, m |
| 1.89, m | 1.91, m | 1.99, m | 2.20, m | |
| 5 | - | - | - | - |
| 6 | 3.37, m | 3.50, m | 2.87, d, 2.7 | 3.12, d, 2.7 |
| 7 | 5.08,m | 5.12, d, 4.5 | 4.10, brs | 4.36, d, 2.2 |
| 8 | - | - | - | - |
| 9 | 1.94, m | - | - | - |
| 10 | - | - | - | - |
| 11 | 1.24, m | 1.15, m | 1.97, m | 1.66, m |
| 1.66, m | 2.05, m | 2.07, m | ||
| 12 | 1.25, m | 1.51, m | 1.34, m | 1.45, m |
| 1.96, m | 1.68, m | 1.88, m | 1.95, m | |
| 13 | - | - | - | - |
| 14 | 1.80, m | 2.39, m | 2.00, m | 2.23, m |
| 15 | 1.36, m | 1.45, m | 1.23, m | 1.66, m |
| 1.48, m | 1.69, m | 2.07, m | ||
| 16 | 1.24, m | 1.25, m | 1.25, m | 1.30, m |
| 1.66, m | 1.68, m | 1.63, m | 1.80, m | |
| 17 | 1.25, m | 1.28, m | 1.14, m | 1.19, m |
| 18 | 0.54, s | 0.54, s | 0.57, s | 0.61, s |
| 19 | 0.91, s | 0.96, s | 1.17, s | 1.25, s |
| 20 | 2.00, m | 1.98, m | 2.00, m | 2.02, m |
| 21 | 0.99, d, 6.6 | 0.98, d, 6.1 | 0.98, d, 6.3 | 0.99, d, 6.6 |
| 22 | 5.19, dd, 15.4, 7.9 | 5.19, dd, 15.1, 7.8 | 5.18, dd, 15.1, 8.0 | 5.16, dd, 15.2, 7.6 |
| 23 | 5.21, dd, 15.4, 7.1 | 5.35, dd, 15.1, 7.0 | 5.20, dd, 15.1, 7.2 | 5.18, dd, 15.2, 6.9 |
| 24 | 2.15, m | 1.98, m | 1.84, m | 1.84, m |
| 25 | 1.41, m | 1.45, m | 1.43, m | |
| 26 | 0.74, d, 6.9 | 0.97, s | 0.79, d, 4.1 | 0.81, d, 4.5 |
| 27 | 3.16, m | 1.02, s | 0.80, d, 4.1 | 0.89, d, 4.5 |
| 3.32, m | ||||
| 28 | 0.92, d, 6.8 | 0.90, d, 6.8 | 0.88, d, 6.8 | 0.89, d, 6.8 |
| 3-OH | 4.21, d, 5.4 | 4.33, d, 3.6 | 4.68, brs | |
| 5-OH | 3.58, s | 5.00, s | ||
| 6-OH | 4.49, d, 5.6 | 4.76, d, 5.5 | ||
| 7-OH | 4.76, brs | |||
| 9-OH | 5.19, s | |||
| 25-OH | 4.08, s | |||
| 27-OH | 4.30, m |
a Measured in DMSO-d6; b Measured in CDCl3.
13C NMR spectral data of new compounds 1–3 (75 MHz for 13C).
| No. | 1a | 2a | 3a | 3b |
|---|---|---|---|---|
| 1 | 32.5 | 26.9 | 30.6 | 31.0 |
| 2 | 31.2 | 31.0 | 30.8 | 31.0 |
| 3 | 66.0 | 65.8 | 67.0 | 68.8 |
| 4 | 40.2 | 40.2 | 39.0 | 39.2 |
| 5 | 74.5 | 73.7 | 62.6 | 63.4 |
| 6 | 72.1 | 71.6 | 60.0 | 60.3 |
| 7 | 119.5 | 120.3 | 65.0 | 67.0 |
| 8 | 139.7 | 141.1 | 126.2 | 126.7 |
| 9 | 42.3 | 77.3 | 134.4 | 137.2 |
| 10 | 36.6 | 39.6 | 37.3 | 38.0 |
| 11 | 27.8 | 26.9 | 22.4 | 23.2 |
| 12 | 38.9 | 35.0 | 36.1 | 36.3 |
| 13 | 43.0 | 43.3 | 41.5 | 42.1 |
| 14 | 54.2 | 50.1 | 51.3 | 51.3 |
| 15 | 22.6 | 22.6 | 29.1 | 23.1 |
| 16 | 27.8 | 27.8 | 22.1 | 29.4 |
| 17 | 55.3 | 55.5 | 53.8 | 54.5 |
| 18 | 12.1 | 11.7 | 11.3 | 11.7 |
| 19 | 17.7 | 21.4 | 22.5 | 23.8 |
| 20 | 40.1 | 40.1 | 40.0 | 40.7 |
| 21 | 21.0 | 20.9 | 20.8 | 21.2 |
| 22 | 135.7 | 135.8 | 135.5 | 135.0 |
| 23 | 130.3 | 130.5 | 131.3 | 132.3 |
| 24 | 36.9 | 47.2 | 42.1 | 43.0 |
| 25 | 40.5 | 70.7 | 32.5 | 33.3 |
| 26 | 13.1 | 26.0 | 19.5 | 19.9 |
| 27 | 64.4 | 28.3 | 19.8 | 20.2 |
| 28 | 18.3 | 15.0 | 17.4 | 17.8 |
a Measured in DMSO-d6; b Measured in CDCl3.
Scheme 1Plausible biosynthetic pathway of 1–13.
Cytotoxic activities of isolated compounds 1–13 (IC50: μg/mL).
| Compounds | MCF-7 | SF-268 | NCI-H460 | Compounds | MCF-7 | SF-268 | NCI-H460 |
|---|---|---|---|---|---|---|---|
| >50 | >50 | >50 | >50 | >50 | >50 | ||
| >50 | >50 | >50 | 24.3 | 15.5 | 19.8 | ||
| 18.1 | 13.0 | 23.5 | >50 | >50 | >50 | ||
| >50 | >50 | >50 | 17.3 | 27.8 | 23.7 | ||
| >50 | >50 | >50 | 27.4 | 25.1 | 23.7 | ||
| >50 | >50 | >50 | >50 | >50 | >50 | ||
| 4.0 | 41.0 | 25.1 | >50 | >50 | >50 |
Concentration range: 1.56–100 μg /mL; IC50: half maximal inhibitory concentration.